Enliven Therapeutics COO Patel sells $134,957 in stock

Enliven Therapeutics NASDAQ:ELVN Chief Operating Officer Anish Patel sold 6,667 shares of common stock on September 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The clinical-stage biotech company, currently valued at $1.1 billion, has caught analysts’ attention with price targets ranging from $33 to $52. The sales were executed at a weighted average price of $20.2426, resulting in a total transaction value of $134,957. Prices ranged from $19.915 to $20.64. According to InvestingPro analysis, the company maintains a strong financial position with more cash than debt and a healthy current ratio of 32.6x.

Following the transaction, Patel indirectly holds 283,308 shares through The Patel / Dong Family Trust.

The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2024.

In other recent news, Enliven Therapeutics announced the pricing of a $200 million public offering, involving 8,394,737 shares of common stock at $19.66 per share. The offering also includes pre-funded warrants for up to 1,780,263 shares at $19.659 per warrant, with an exercise price of $0.001 per share. In addition, several investment firms have shown positive sentiment towards the company. H.C. Wainwright raised its price target for Enliven Therapeutics to $48 from $40, maintaining a Buy rating, following promising results from the Phase 1a/1b ENABLE trial of ELVN-001 for chronic myelogenous leukemia (CML). BTIG also reiterated its Buy rating with a $45 price target, highlighting the potential of ELVN-001 as a next-generation tyrosine kinase inhibitor. TD Cowen echoed this sentiment, maintaining a Buy rating and noting the strong proof-of-concept data for ELVN-001 presented at the European Hematology Association meeting. Goldman Sachs initiated coverage with a Buy rating and a $37 price target, emphasizing positive Phase 1 data and a notable major molecular response rate for ELVN-001. These developments reflect growing confidence in Enliven Therapeutics’ potential in the CML market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.